N‐terminal pro‐B‐type natriuretic peptide and prognosis in Caucasian vs. Asian patients with heart failure

N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP) is the most frequently used biomarker in heart failure (HF), but its prognostic utility across ethnicities is unclear.

[1]  W. Paulus,et al.  A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.

[2]  Deepak L. Bhatt,et al.  Racial/Ethnic differences in B-type natriuretic peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from Get With The Guidelines-Heart Failure. , 2013, JACC. Heart failure.

[3]  C. Frampton,et al.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.

[4]  G. Navis,et al.  Drawbacks and Prognostic Value of Formulas Estimating Renal Function in Patients With Chronic Heart Failure and Systolic Dysfunction , 2006, Circulation.

[5]  W. Paulus,et al.  Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation , 2016, European journal of heart failure.

[6]  Eun-Seok Jeon,et al.  Characteristics, Outcomes and Predictors of Long-Term Mortality for Patients Hospitalized for Acute Heart Failure: A Report From the Korean Heart Failure Registry , 2011, Korean circulation journal.

[7]  L. Foucan,et al.  NT-proBNP, Cardiometabolic Risk Factors, and Nutritional Status in Hemodialysis Patients , 2017, International journal of nephrology.

[8]  Antoni Bayes-Genis,et al.  NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. , 2006, European heart journal.

[9]  A. Keren,et al.  Ethnic disparity in the clinical characteristics of patients with heart failure , 2015, European journal of heart failure.

[10]  D. Lloyd‐Jones,et al.  Association of atrial fibrillation and amino-terminal pro-brain natriuretic peptide concentrations in dyspneic subjects with and without acute heart failure: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. , 2007, American heart journal.

[11]  V. Cameron,et al.  The Singapore Heart Failure Outcomes and Phenotypes (SHOP) study and Prospective Evaluation of Outcome in Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction (PEOPLE) study: rationale and design. , 2013, Journal of cardiac failure.

[12]  A. Hoes,et al.  B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. , 2013, Journal of the American College of Cardiology.

[13]  C. Frampton,et al.  Superior performance of N‐terminal pro brain natriuretic peptide for diagnosis of acute decompensated heart failure in an Asian compared with a Western setting , 2017, European journal of heart failure.

[14]  Hans L Hillege,et al.  Effect of moderate or intensive disease management program on outcome in patients with heart failure: Coordinating Study Evaluating Outcomes of Advising and Counseling in Heart Failure (COACH). , 2008, Archives of internal medicine.

[15]  D. McManus,et al.  The complex relationship of race to outcomes in heart failure with preserved ejection fraction. , 2015, The American journal of medicine.

[16]  Alan S Maisel,et al.  How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure. Results from the Breathing Not Properly Multinational Study. , 2006, American heart journal.

[17]  J. Gardin,et al.  Racial differences in incident heart failure among young adults. , 2009, The New England journal of medicine.

[18]  Y. Chan,et al.  Impact of race on morbidity and mortality in patients with congestive heart failure: a study of the multiracial population in Singapore. , 2009, International journal of cardiology.

[19]  P. Ponikowski,et al.  Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. , 2010, Journal of the American College of Cardiology.

[20]  K. Swedberg,et al.  Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. , 2008, Journal of the American College of Cardiology.

[21]  Tiny Jaarsma,et al.  Design and methodology of the COACH study: a multicenter randomised Coordinating study evaluating Outcomes of Advising and Counselling in Heart failure , 2004, European journal of heart failure.

[22]  P. Ponikowski,et al.  International differences in clinical characteristics, management, and outcomes in acute heart failure patients: better short‐term outcomes in patients enrolled in Eastern Europe and Russia in the PROTECT trial , 2014, European journal of heart failure.

[23]  F. McAlister,et al.  Ethnic differences in 1-year mortality among patients hospitalised with heart failure , 2011, Heart.

[24]  Robert N. Doughty,et al.  The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. , 2011, European heart journal.

[25]  J. Sanderson,et al.  Plasma brain natriuretic peptide — an independent predictor of cardiovascular mortality in acute heart failure , 1999, European journal of heart failure.

[26]  B. Riegel,et al.  Racial Differences in Clinical Treatment and Self‐Care Behaviors of Adults With Chronic Heart Failure , 2015, Journal of the American Heart Association.

[27]  D. J. Veldhuisen,et al.  Anaemia and renal dysfunction are independently associated with BNP and NT‐proBNP levels in patients with heart failure , 2007, European journal of heart failure.

[28]  M. Kinoshita,et al.  High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. , 2000, Journal of the American College of Cardiology.

[29]  G. Lip,et al.  Heart failure—the importance of ethnicity , 2004, European journal of heart failure.

[30]  L. Jorde,et al.  Genetic variation, classification and 'race' , 2004, Nature Genetics.

[31]  Akshay S. Desai,et al.  Race Influences the Safety and Efficacy of Spironolactone in Severe Heart Failure , 2013, Circulation. Heart failure.

[32]  J. Hollander,et al.  B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[33]  C. Lam,et al.  The middle child in heart failure: heart failure with mid‐range ejection fraction (40–50%) , 2014, European journal of heart failure.

[34]  P. Ponikowski,et al.  Atrial fibrillation impairs the diagnostic performance of cardiac natriuretic peptides in dyspneic patients: results from the BACH Study (Biomarkers in ACute Heart Failure). , 2013, JACC. Heart failure.

[35]  N. Bayley,et al.  Failure , 1890, The Hospital.

[36]  Y. Pinto,et al.  Amino-terminal pro-B-type natriuretic peptide testing in renal disease. , 2008, The American journal of cardiology.